Cardiometabolic Risk Reduction Through Selective Amylin Receptor Agonism

Obesity remains a major modifiable driver of cardiovascular disease. Emerging antiobesity pharmacotherapies demonstrate substantial weight loss alongside improvements in multiple cardiometabolic parameters. This literature review summarizes the early clinical studies of eloralintide, a selective long-acting amylin receptor agonist, and evaluates whether its weight loss and cardiometabolic effects may be relevant to cardiovascular risk reduction. Early clinical studies suggest a potentially distinct and favorable cardiometabolic profile for eloralintide, including reductions in body weight, pulse rate, blood pressure, inflammatory markers, lipid parameters, and preferential fat mass loss. The reduction in pulse rate stands out as it contrasts with the increase in heart rate that is associated with glucagon-like peptide-1 receptor agonists. The favorable profile may be further supported by eloralintide’s preferential fat mass loss and improvements in both the high-sensitivity C-reactive protein and lipid markers. While these findings are promising, current evidence is limited as it is based on preclinical, phase 1, and phase 2 studies with relatively small sample sizes and short durations. No amylin receptor agonist, including eloralintide, has been evaluated in a dedicated cardiovascular outcomes trial, and their ability to reduce major adverse cardiovascular events remain to be studied. Therefore, epidemiological benchmarks should be viewed as contextual rather than predictive. Future clinical studies and dedicated cardiovascular outcomes trials will be essential to determine whether these early cardiometabolic improvements translate to clinically meaningful cardiovascular risk reduction.